Yes, I realise that it's in the exclusion criteria. But one...

Yes, I realise that it's in the exclusion criteria. But one reason that another participant hasn't been dosed is higher than expected antibodies in the HCV population to AAV-8 according to Hoyland's earlier post.

How is it that this information is easily found on the internet, yet management didn't feel that shareholders need to know this price sensitive information? Look at how much the sp has crashed since Hoyland posted this information, yet not a word from management. BLT may subscribe to the whole 'no news is good news' mantra, but I'm calling BS.

As BLT have previously stated that TT-034 can only be administered once due to patients developing antibodies to the AAV-8 vector, I can only conclude that TT-034 will not be effective for many HCV positive people. There is no way, in that event, that it can ever compete with Sovaldi, one-shot or not.